MRK241206P84000
- 0.01
- 0.000.00%
Merck & Co Newsroom
AstraZeneca (AZN.US) and MSD (MRK.US) announce long-term results from phase 3 Olympia clinical trial
Lynparza is a “first-in-class” PARP inhibitor and the first synthetic lethal targeted therapy to target cells/tumors with homologous recombinant repair (HRR) defects (such as cells carrying BRCA1 and/or BRCA2 mutations).
AstraZeneca, Merck's Lynparza Shows Prolonged Survival Benefit in Early Breast Cancer Patients
Market Climbs on CPI Inflation and Likelihood of Rate Cuts | Livestock
BofA Securities Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $121
Express News | Lynparza® (Olaparib) Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in Olympia Phase 3 Trial
BofA Securities Maintains Merck & Co(MRK.US) With Buy Rating, Cuts Target Price to $121
Is Merck & Co., Inc. (MRK) the Best American Dividend Stock to Buy Right Now?
BofA Restarts Coverage of 11 Large-cap Biopharmas
Market Falls Wednesday, but Googles Chip Impresses | WST
EMD Serono Appoints Miguel Fernández Alcalde to Lead North American Healthcare Business
10 Health Care Stocks With Whale Alerts In Today's Session
Google's Quantum Chip Might Have Contacted Parallel Universes | Live Stock
Dow Down 150 Points On Losses For Shares Of Caterpillar, 3M
MRK's Keytruda & Lynparza Combo Meets Goal in Ovarian Cancer Study
Today's Analyst Rating | Tesla Price Target Raised to $400 by Morgan Stanley, Oracle Price Target Raised to $194 by Citi
Express News | B of A Securities Reinstates Buy on Merck & Co, Announces $121 Price Target
Merck & Co Analyst Ratings
Berenberg Bank Maintains Merck & Co(MRK.US) With Buy Rating, Cuts Target Price to $125
Monday Market Falls, Chinese Stocks Climb, Indices Rebalance | Live Stock
Merck Reveals Mixed Data From Keytruda/Lynparza Regime In Ovarian Cancer